Biofrontera Inc. (NASDAQ:BFRI) Shares Shorted: Short Interest Down 68.4% in September

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a large decline in short interest in September. As of September 30th, there was short interest totaling 146,851 shares, a decline of 68.4% from the September 15th total of 464,825 shares. Approximately 1.1% of the company’s shares are short sold. Based on an average daily volume of 403,096 shares, the short-interest ratio is presently 0.4 days.

Biofrontera Stock Down 5.8%

Shares of BFRI traded down $0.05 on Tuesday, reaching $0.87. The stock had a trading volume of 239,146 shares, compared to its average volume of 415,528. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.08 and a current ratio of 1.18. Biofrontera has a 12-month low of $0.55 and a 12-month high of $1.66. The firm has a market capitalization of $12.94 million, a price-to-earnings ratio of -1.94 and a beta of 0.86. The company has a 50-day simple moving average of $1.29 and a 200-day simple moving average of $1.11.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. The company had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $9.50 million. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%. Sell-side analysts predict that Biofrontera will post -0.60 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Wall Street Zen downgraded shares of Biofrontera from a “buy” rating to a “hold” rating in a research note on Sunday, September 20th. Finally, Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Biofrontera has a consensus rating of “Hold”.

About Biofrontera

Biofrontera Inc (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing dermatology products in the United States. The company’s activities center on treatments for actinic keratosis, a common precancerous skin condition caused by sun exposure.

Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription treatment used in combination with photodynamic therapy to treat mild-to-moderate actinic keratoses on the face and scalp.